Research Article
BibTex RIS Cite

Investigation of Anticancer Activity of Ochratoxin Against Prostate Cancer Cell Line

Year 2025, Volume: 4 Issue: 3, 142 - 149

Abstract

Prostate cancer is one of the most prevalent malignancies among men and remains a significant public health concern due to its high mortality rate, despite the availability of current treatment strategies. Ochratoxin, a naturally occurring mycotoxin, has attracted considerable attention for its diverse biological activities. This study explores the anticancer potential of ochratoxin in prostate cancer cell lines. Cell viability was evaluated following treatment with defined concentrations of ochratoxin, and apoptotic mechanisms, along with gene expression profiles, were analyzed. The results demonstrate that ochratoxin suppresses cell proliferation and induces apoptosis in a dose-dependent manner. These findings suggest that ochratoxin may represent a promising candidate for prostate cancer therapy. However, further in vivo studies are necessary to confirm its clinical relevance and therapeutic applicability.

Project Number

2209 projesi

References

  • [1] IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Naturally Occurring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. Lyon, France: World Health Organization; International Agency for Research on Cancer; 1993. Volume 56.
  • [2] Więckowska M, Cichon N, Szelenberger R, Gorniak L, Bijak M. Ochratoxin A and Its Role in Cancer Development: A Comprehensive Review. Cancers. 2024;16(20):3473.
  • [3]Meki AR, Hussein AA. Melatonin reduces oxidative stress induced by ochratoxin A in rat liver and kidney. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology. 2001;130:305–313.
  • [4] Liang R, Shen XL, Zhang B, Li Y, Xu W, Zhao C, Luo Y, Huang K. Apoptosis signal-regulating kinase 1 promotes Ochratoxin A-induced renal cytotoxicity. Scientific Reports. 2015;5:8078.
  • [5] Ali, R., Khan, M. R., & Rehman, S. (2016). Toxicity study of ochratoxin A using HEK293 and HepG2 cell lines. Human & Experimental Toxicology, 35(5), 491–500.
  • [6] Kumar, A., Sharma, V., & Singh, N. (2021). Studies on cytotoxic effects of ochratoxin A extracts on human cell lines (Hfl-1 and Hep-2). International Journal of Toxicological Research, 11(2), 45–52.
  • [7] Skrzydlewski, P., Twarużek, M., & Grajewski, J. (2022). Cytotoxicity of mycotoxins and their combinations on different cell lines: A review. Toxins, 14(4), 244.
  • [8] Heussner, A. H., & Bingle, L. E. (2015). Comparative ochratoxin toxicity: A review of the available data. Toxins, 7(10), 4253–4282.
  • [9] Sava, V., Velasquez, A., Song, S., & Sanchez-Ramos, J. (2006). Effects of ochratoxin A on mitochondrial respiration and cell cycle in Vero cells. Toxicology and Applied Pharmacology, 213(2), 190–197.
  • [10] Zhang, Y., Wang, Y., Li, X., Liu, Y., & Zhao, Y. (2018). Ochratoxin A induces apoptosis in MCF-7 cells via reactive oxygen species-mediated mitochondrial pathway. Food and Chemical Toxicology, 112, 1–10. [11] Migliaccio G, Ferraro R, Wang Z, Cristini V, Dogra P, Caserta S. Exploring Cell Migration Mechanisms in Cancer: From Wound Healing
There are 10 citations in total.

Details

Primary Language English
Subjects Toxicology
Journal Section Research Article
Authors

Neşe Başak Türkmen 0000-0001-5566-8321

İrem Sena Küçük This is me 1111-1111-1111-1111

Irmak Icen Taskın 0000-0002-1612-0563

Şeyma Yaşar 0000-0003-1300-3393

Dilan Aşkın Özek 0000-0001-9075-4807

Hande Yüce 0000-0003-2907-2019

Project Number 2209 projesi
Publication Date November 28, 2025
Submission Date October 9, 2025
Acceptance Date October 31, 2025
Published in Issue Year 2025 Volume: 4 Issue: 3

Cite

EndNote Başak Türkmen N, Küçük İS, Icen Taskın I, Yaşar Ş, Aşkın Özek D, Yüce H Investigation of Anticancer Activity of Ochratoxin Against Prostate Cancer Cell Line. Anatolian Journal of Pharmaceutical Sciences 4 3 142–149.

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.